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The United Kingdom (UK) was the first European country to introduce a national immunisa-
tion program for shingles (2013–2014). That year, vaccination coverage ranged from 50 to
64% across the UK, but uptake has declined ever since. This study explored determinants
of the acceptance of the shingles vaccine in the UK.
Methods
Vaccinated and unvaccinated individuals, who were eligible for the last catch-up cohort of
the 2014–2015 shingles vaccination campaign, were identified using the Clinical Practice
Research Datalink (the National Health Service data research service) and invited to partici-
pate by their general practitioner (GP). An anonymised self-administered questionnaire was
developed using the Health Belief Model as a theoretical framework, to collect data on
demographic and socio-economic characteristics, health status, knowledge, influences,
experiences and attitudes to shingles and the shingles vaccine. Multivariable logistic regres-
sion was used to identify the factors associated with vaccination. Physicians’ views concern-
ing perceived barriers to vaccination were also assessed.
Results
Of the 2,530 questionnaires distributed, 536 were returned (21.2%) from 69 general prac-
tices throughout the UK. The majority of responders were female (58%), lived in care homes
(56%) and had completed secondary or higher education (88%). There were no differences
between vaccinated and unvaccinated responders. Being offered the shingles vaccine by a
GP/nurse (odds ratio (OR) = 2.3), and self-efficacy (OR = 1.2) were associated with being
vaccinated (p<0.05). In contrast, previous shingles history (OR = 0.4), perceived barriers to
vaccination (OR = 0.7) and perceived control of the disease (OR = 0.7) were associated
with not being vaccinated against shingles (p<0.05). Less than half (44.0%) of GPs were
aware of the local communication campaigns regarding shingles and the shingles vaccine.
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Conclusions
Socio-psychological factors largely influence shingles vaccination acceptance in this study.
The results add to existing evidence that healthcare providers (HCPs) have a pivotal role
against vaccine hesitancy. Campaigns focusing on GPs and accessible information offered
to eligible members of the public can further enhance shingles vaccine uptake.
Introduction
Shingles (herpes zoster) is the clinical manifestation of a reactivation of latent varicella–zoster
virus. The incidence of shingles in the United Kingdom (UK) ranges from 3.4–5.0/1,000 per-
son-year and increases to 7.9–8.8/1,000 person-year among those aged 70–79 [1]. Shingles can
present several decades after the initial infection with varicella–zoster virus (i.e. varicella), and
is characterised by a vesicular skin rash, usually lasting 2 to 4 weeks, often preceded or accom-
panied by acute pain or itching. About 10–20% of patients with shingles may develop post-her-
petic neuralgia (PHN), a debilitating complication where pain persists for more than 3 months
[2].
UK was the first European country to introduce shingles vaccination in the 2013–2014
national immunisation programme, targeting adults aged 70 or 79 years (catch-up cohort).
For the second year of the programme, in 2014–2015, people aged 78 years on the 1st Septem-
ber 2014 were also targeted for the catch-up programme. The introduction of the shingles vac-
cine led to about 17,000 fewer episodes of shingles and 3,300 of PHN among 5.5 million
eligible individuals in the first 3 years of the programme in England [3]. Vaccination coverage
ranged from 50 to 64% across the UK during the first year of the campaign [4–7]. However,
uptake has declined in subsequent years [8].
Vaccination hesitancy is a well-recognised obstacle to the success of vaccination pro-
grammes [9]. As with any other health-related decision-making process, vaccination behav-
iour is often influenced by demographic, socio-economic and socio-psychological factors,
including beliefs and perceptions towards vaccines [10–13]. Socio-psychological factors are of
particular interest as they may be amenable to change.
Few studies have explored factors associated with shingles vaccination [14–18]. Their gen-
eralizability remains limited to particular contexts or regions [14,15]. Previous research is also
limited by its reliance on self-reported vaccination status [16] and lack of theoretical underpin-
ning model [14–16].
This study sought to address some of these shortcomings. We aimed to explore, for the first
time to our knowledge, the constellation of factors which may influence shingles vaccine
uptake in the UK. To this end, we employed a theory-driven framework for attitudinal assess-
ment, the Health Belief Model (HBM). The HBM has been widely used to study health-seeking
behaviours including vaccine acceptance in the elderly, mainly influenza vaccine [17–19], but
also the shingles vaccine [20,21]. As a secondary aim, GPs’ views concerning barriers to shin-
gles vaccination were also assessed.
Methods
Sampling strategy
The Clinical Practice Research Datalink (CPRD), the UK governmental data research service
based on anonymised primary care records, was used to identify individuals vaccinated and
The ZOOM Study
PLOS ONE | https://doi.org/10.1371/journal.pone.0220230 August 1, 2019 2 / 13
2017. Bricout H, Torcel-Pagnon L, Wheelock A and
Sevdalis N contributed to the conception/design of
the study. Matthews I, Lu X, Lecomte C and Almas
MF drafted the initial manuscript. Bricout H and
Torcel-Pagnon L were employee of Sanofi Pasteur
MSD. Matthews I and Lu X are employed by MDS.
Wheelock A and Sevdalis N have received
consultancy fees from of Sanofi Pasteur MSD and
MDS. Lecomte C and Almas M are employed by
IQVIA which received funds from Sanofi Pasteur
MSD and MSD to conduct the study. The funder
provided support in the form of salaries for authors
Bricout H, Torcel-Pagnon L, Matthews I, and Lu X,
but did not have any additional role in the study
design, data collection of the manuscript. The
specific roles of these authors are articulated in the
“author contributions” section.
Competing interests: Bricout H and Torcel-Pagnon
L were employee of Sanofi Pasteur MSD and are
currently employed by Sanofi Pasteur. Matthews I
and Lu X are employed by MDS. Wheelock A and
Sevdalis N have received consultancy fees from of
Sanofi Pasteur MSD and MDS. Lecomte C and
Almas MF are employed by IQVIA which received
funds from Sanofi Pasteur MSD and MSD to
conduct the study. Sevdalis N’s research is
supported by the NIHR Collaboration for
Leadership in Applied Health Research and Care
South London at King’s College Hospital NHS
Foundation Trust. Sevdalis N is a member of King’s
Improvement Science, which is part of the NIHR
CLAHRC South London and comprises a specialist
team of improvement scientists and senior
researchers based at King’s College London. Its
work is funded by King’s Health Partners (Guy’s
and St Thomas’ NHS Foundation Trust, King’s
College Hospital NHS Foundation Trust, King’s
College London and South London and Maudsley
NHS Foundation Trust), Guy’s and St Thomas’
Charity, the Maudsley Charity and the Health
Foundation. Sevdalis N’ research is further
supported by an unrestricted research grant by
Sanofi Pasteur, as part of an ESRC King’s
Interdisciplinary Social Sciences Doctoral Training
Centre Collaborative Studentship (2017-20). The
funders do not have any editorial control over the
work reported in this article. The views expressed
are those of the author(s) and not necessarily
those of King’s, the ESRC, the NHS, the NIHR or
the Department of Health. This does not alter our
adherence to PLOS ONE policies on sharing data
and materials.
unvaccinated against shingles among those eligible for the last catch-up cohort of the 2014–
2015 vaccination campaign (aged 79), thus not eligible for the following campaign. All individ-
uals born in 1934 and 1935 were mapped to their practices. Eligible individuals were sent an
anonymous self-administered paper questionnaire from their GP’s practice.
Our sample size calculation is based on the estimation that a sample size of 500 patients (1:1
vaccinated versus unvaccinated) could detect an odds ratio (OR) ranging between 1.66–2.08
(two-sided α = 5%, β = 80%). This is consistent with the ORs observed in a study investigating
the impact of shingles vaccine awareness on immunisation among people aged�50 years [22].
A response rate of 20% was expected as elderly individuals are less likely to return completed
postal questionnaires [23]. Thus 2,500 individuals were targeted.
Ninety-one practices with�30 individuals in each birth cohort were selected based on their
interest to participate, geographic dispersion across UK (England, Wales, Scotland, and North-
ern Ireland), practice size and research experience. They were provided with a list of poten-
tially eligible individuals based on their year of birth who were randomly selected (up to 60 per
practice). Study responder characteristics, including vaccination status (confirmed by the GPs
in the primary care records transferred to CPRD anonymously), were assessed after 100 and
300 questionnaires were received, to monitor any ongoing selection bias (to get closer to a 1:1
ratio of individuals vaccinated and unvaccinated against shingles).
Data collection
The HBM underpinned the development of the attitudinal assessment instrument. We
assessed perceived susceptibility, severity, barriers, cue to action and self-efficacy (i.e. confi-
dence in one’s ability to take action) [24,25] in relation to shingles and the shingles vaccine.
The instrument also measured socio-demographic variables and was informed by recent evi-
dence on behavioural factors that affect vaccination uptake [19]. Further, health decision-mak-
ing preferences [26,27], knowledge [12], perceived control of the disease [28,29] and trust in
key vaccination stakeholders [30] were also investigated based on prior evidence of the rele-
vance of these factors on vaccination uptake. After concept elaboration, cultural and semantic
review, conceptual equivalence check and independent proofreading, the survey instrument
was pilot tested in 5 healthy adults eligible for the shingles vaccination campaign recruited
from UK community centres to ensure feasibility and comprehension. The participants were
asked to complete the questionnaire, to comment on the response options and on items diffi-
cult to understand, suggesting alternative wording, followed by cognitive debriefing. After-
wards there was another round of instrument developer review and final proofreading.
Objective vaccination data collected included vaccination status, gender and year of birth,
retrieved directly from the CPRD.
GPs’ views about shingles vaccination were also assessed. A paper survey was sent to each
GP practice, which assessed vaccination practices, local communication campaigns on shingles
vaccination and perceived barriers to shingles vaccination.
Data analysis
The survey items were answered on multiple or alternate choice and 7-point Likert scales
[31,32]. All analyses were performed using SAS. Descriptive statistics were produced for all
survey responses. Items reflecting HBM constructs were aggregated into the relevant compos-
ite constructs, where internal consistency was considered satisfactory if Cronbach’s alpha coef-
ficient was�0.70 [33]. Bivariate analysis (chi-squared and t-tests) compared responders versus
non-responders’ socio-demographic characteristics and vaccination status, and vaccinated
versus unvaccinated responder’s answers to the survey (two-sided tests, α = 5%).
The ZOOM Study
PLOS ONE | https://doi.org/10.1371/journal.pone.0220230 August 1, 2019 3 / 13
A multivariable logistic regression model was produced using HBM constructs and other
socio-psychological factors, as well as socio-demographic and health factors, as independent
variables; and objective vaccination status as the dependent variable.
Complete case analysis was used for the multivariable model. Robustness was assessed with
sensitivity analyses, assuming an arbitrary missing pattern using Markov chain Monte Carlo.
Multiple imputation for all Likert-scale items with missing data used the established procedure
by Rubin et al [34]. GP survey items were analysed descriptively.
Ethics review
The study protocol was approved by the National Health Service Research Ethics Committee
(reference number: 15/SC/0503), the National Research Ethics Service, the local NHS trust of
the practices and the Independent Scientific Advisory Committee for CPRD access. A partici-
pant information sheet was provided to the individuals with the survey. An individual’s deci-
sion to complete and return the survey was interpreted as consent to participate.
Results
Responders characteristics
From the 91 contacted GP practices, 84 (92.3%) accepted to participate. Among 2,530 ques-
tionnaires distributed by those practices, 536 were returned (21.2%) from 69 practices
throughout the UK. There were relatively fewer responders from England and more from
Northern Ireland and Scotland. The shingles vaccine coverage was 70.1% among responders
and 58.9% among non-responders (Table 1).
Most responders were female (57.8%), of white ethnicity (98.8%), belonged to urban prac-
tices (61.8%), living in a care home (55.7%), had completed high/secondary school or higher









Male 1087 (43.0%) 226 (42.2%) 861 (43.2%)
Female 1443 (57.0%) 310 (57.8%) 1133 (56.8%)
Missing 0 0 0
Shingles vaccination status 0.123
Vaccinated 1318 (61.4%) 344 (70.1%) 974 (58.9%)
Unvaccinated 828 (38.6%) 147 (29.9%) 681 (41.1%)
Missing 384 45 339
Nation <0.001
England 1515 (59.9%) 273 (50.9%) 1242 (62.3%)
Northern Ireland 439 (17.4%) 118 (22.0%) 321 (16.1%)
Scotland 160 (6.3%) 53 (9.9%) 107 (5.4%)
Wales 416 (16.4%) 92 (17.2%) 324 (16.2%)
Missing 0 0 0
GP’s geographical location <0.001
Urban 1709 (75.3%) 289 (61.8%) 1420 (78.8%)
Rural 561 (24.7%) 179 (38.2%) 382 (21.2%)
Missing 260 68 192
p-value for Chi-Square test (two-sided)
https://doi.org/10.1371/journal.pone.0220230.t001
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(88.4%), and were not engaged in any professional/caring activity (71.8%). Only half of
responders reported their income. Many responders (77.0%) considered themselves to be in
good health. Nonetheless, two-thirds of responders reported having at least 1 medical condi-
tion; diabetes being the most common. Unvaccinated responders presented a higher preva-
lence of diabetes and history of shingles in the past than vaccinated responders (S1 Table).
Knowledge and perceptions of shingles and the shingles vaccine
The average self-assessed knowledge about shingles by the responders was 3.4 on the 7-point
scale. True knowledge about shingles was further assessed by 4 statements (Fig 1). Regardless
of vaccination status, most of the responders answered correctly, thus exhibiting accurate
knowledge. However, approximately one-third of participants did not know that shingles
could not be caught from another person with shingles, nor that the chance of developing
shingles increases with age.
There were few significant differences on perceptions of shingles and the shingles vaccine
between vaccinated and unvaccinated responders (p<0.05) as summarised in Table 2 (com-
plete list of studied determinants is displayed in S1 Table).
Vaccinated responders perceived lower susceptibility to shingles, scored slightly higher on
the perceived benefits of the shingles vaccine and on vaccine related self-efficacy, and felt less
constrained by the practical barriers as compared with unvaccinated. In contrast, unvaccinated
responders perceived more barriers to the shingles vaccine and had a higher perceived control
of the disease without the vaccine.
Fig 1. True knowledge about shingles among responders. Note: “Shingles can be caught from someone else who has shingles.” (Correct answer: false); “Shingles can lead
to long-lasting, severe pain.” (Correct answer: true); “The chance of developing shingles increases with age.” (Correct answer: true); “Shingles is caused by the same virus
that causes chickenpox.” (Correct answer: true).
https://doi.org/10.1371/journal.pone.0220230.g001
The ZOOM Study
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Responders were generally engaged with GPs in medical decision-making (>85%) and
highly trusted their GP and the NHS recommendations regarding shingles. For most respond-
ers, information about the shingles vaccine was obtained whilst they were attending the doc-
tor’s surgery (75.9% among vaccinated and 67.3% among unvaccinated, p = 0.05). Vaccinated
responders were more likely than the unvaccinated ones to have been offered the shingles vac-
cine by their GP/nurse, told about shingles by their GP/nurse, advised to receive the vaccine
by vaccinated relatives or friends, or know someone who had shingles vaccination.





Vaccinated (N = 344) Unvaccinated (N = 147) p-value OR 95% CI
n (%) Mean (SD) n (%) Mean (SD)
History of shingles 344 145
No1 239 (69.5) - 81 (55.9) - <0.001 1.01
I don't know/remember1 17 (4.9) - 3 (2.1) -
Yes 88 (25.6) - 61 (42.1) - 0.4�γ 0.2–0.7
Perceived susceptibility 332 3.6 (1.27) 142 3.8 (1.24) 0.036 1.0 0.8–1.3
Perceived benefits 327 5.6 (1.11) 136 5.3 (1.03) 0.002 1.0 0.8–1.4
Perceived barriers 332 2.9 (1.08) 138 3.6 (0.99) <0.001 0.7 0.5–1.0
Practical barriers and Facilitators 329 6.2 (1.40) 129 5.8 (1.62) 0.008 1.0 0.8–1.3
Self-efficacy 316 5.9 (1.80) 127 5.2 (2.16) <0.001 1.2�γ 1.0–1.4
Perceived control of disease 323 2.7 (1.56) 130 3.5 (1.54) <0.001 0.7�γ 0.6–0.9
Did your GP or nurse offer you the shingles
vaccination (through a letter, phone call, text message
or during a visit)?
321 139
I don't know/remember1 35 (10.9%) - 16 (11.5%) -
<0.001
1.01
No1 66 (20.6%) - 56 (40.3%) -
Yes 220 (68.5%) - 67 (48.2%) - 2.3�γ 1.1–4.7
Did your GP or nurse tell you about shingles? 315 131
I don't know/remember1 47 (14.9%) - 13 (9.9%) -
<0.001
1.01
No1 126 (40.0%) - 79 (60.3%) -
Yes 142 (45.1%) - 39 (29.8%) - 0.7 0.3–1.4
Do you know anyone who has had the shingles vaccination? 325 137
I don't know/remember1 19 (5.8%) - 5 (3.6%) - <0.001 1.01
No1 151 (46.5%) - 92 (67.2%) -
Yes 155 (47.7%) - 40 (29.2%) - 1.6 0.8–3.2
Did anyone, among your vaccinated relatives
or friends, advise you to have the shingles vaccination?
325 135
I don't know/remember1 29 (8.9%) - 6 (4.4%) - 0.016 1.01
No1 242 (74.5%) - 117 (86.7%) -
Yes 54 (16.6%) - 12 (8.9%) - 1.6 0.6–4.4
Max-rescaled R-Square (pseudo-R2) 0.3220
CI = Confidence Interval; OR = Odds ratio;
�p � 0.05;
γ direction and significance of effect corroborated in sensitivity analysis.
1 Multivariable model reference category is “Other than yes”. It includes “No”, “I don’t know/remember” and missing.
Note: the complete list of studied determinants is displayed in S1 Table.
https://doi.org/10.1371/journal.pone.0220230.t002
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Determinants of shingles vaccination uptake
As summarized in Table 2, shingles vaccination was associated with GP/nurse vaccine recom-
mendations (OR: 2.3; 95% Confidence Interval (CI): 1.1–4.7; p<0.05) and vaccine related self-
efficacy construct (OR: 1.2; 95% CI: 1.0–1.4; p<0.05). In contrast, non-vaccination was associ-
ated with perceived barriers (OR: 0.7; 95% CI: 0.5–1.0; p<0.05), perceived control of the dis-
ease (OR: 0.7; 95% CI: 0.6–0.9; p<0.05) and previous history of shingles (OR: 0.4, 95% CI: 0.2–
0.7; p<0.05). Approximately one-third of the observations had at least 1 missing variable and
therefore were excluded from the model. Encouragingly, the sensitivity analyses using multiple
imputation corroborated the results from the multivariable model presented in S1 Table.
GPs’ perceptions regarding shingles vaccination in their practices
The majority of GPs considered that their practices had internal procedures/guidelines
(95.1%) and enough staff (90.5%) to provide vaccination information to the elderly and had
materials available for patients (91.7%). Most GPs considered having enough time to provide
vaccination recommendations to their elderly patients (72.7% of those in rural and 57.6% of
those in urban settings). Approximately one-third of GPs either stated that there were no local
communication campaigns (e.g. local radio/TV spot, local newspapers advertisement, etc.)
regarding shingles vaccination or preferred not to answer.
Responses from rural and urban GPs on their opinion about shingles and the shingles vac-
cine were comparable (Fig 2). GPs had a neutral opinion or slightly agreed that shingles was an
economic burden, the shingles vaccine was effective, there was enough information on the
duration of protection of the shingles vaccine, that their patients thought they needed the vac-
cine or were concerned with getting the shingles vaccine. The single injection for the shingles
vaccine was strongly seen as an advantage by the GPs.
Discussion
To the best of our knowledge, this is the first study conducted in the UK investigating the
determinants of the acceptance of the shingles vaccine using a theory-informed instrument
and objectively derived vaccination status. The vaccinated responders were more likely to have
been offered the shingles vaccine by their GP/nurse or advised to take it by their relatives or
friends. They also reported feeling less susceptible to shingles, were more likely to value the
benefits of the shingles vaccine, scored higher on perceived vaccine related self-efficacy and
were significantly less constrained by practical barriers to vaccination. In contrast, unvacci-
nated responders were more likely to report practical barriers to shingles vaccination, and
believed they were more able to control the disease without the vaccine. Our regression model
accounted for one-third of the variability in the shingles vaccination uptake in our sample.
Our results support findings from previous studies and add new insights. Self-reported
knowledge about shingles was limited and consistent with the results of a global survey where
little or no knowledge of shingles was reported across regions [35]. Although, the majority of
UK responders knew shingles is caused by the same virus that causes chickenpox, the majority
did not know or did not remember that shingles cannot be transmitted from another person
with shingles. In addition, 87.1% of the responders had limited knowledge on shingles vaccine,
consistent with existing literature [16]. Our findings are discrepant, however, with those from
a global survey suggesting that responders with prior experience of shingles were more likely
to be aware of shingles and believed they could develop it, indicating they would be more likely
get the vaccine [35]. Data from the US 2007 National Immunization Survey-Adult (NIS-Adult)
indicated that one of the main reasons for not accepting the shingles vaccine was participants
felt vaccination was not needed (34.8%) [36]. Responders who had the disease in the past may
The ZOOM Study
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consider that they do not need the shingles vaccine, either because of increased awareness to
acquired boosted immunity after the first episode of shingles, or because they managed the
previous episode without it. Since the incidence of recurrent shingles and the relationship with
previous episodes are still under investigation [37], it is possible that GPs and individuals con-
sider that the vaccine is not required if the disease occurred in the past.
The study adds to evidence on the pivotal role of provider recommendations regarding get-
ting the shingles vaccine. Consistent with other studies, receiving advice from a GP or another
healthcare provider (HCP) to get the shingles vaccine increases acceptability of the vaccine
[15,16,21,38,39], and may even reverse initial reluctance towards the shingles vaccination [14].
Overall, our results highlight the importance of routine monitoring and addressing vaccina-
tion sentiment among cohorts eligible for shingles vaccination–as this can offer useful insights
regarding objective uptake of vaccination.
Limitations and strengths
The study targeted larger GP practices more familiar with research and where ethical approval
procedures were streamlined. Due to delays in the study implementation, there was an over-
representation of Northern Ireland and underrepresentation of England and Scotland–hence
Fig 2. GPs’ perceptions of shingles and the shingles vaccine (1 = strongly disagree, 7 = strongly agree).
https://doi.org/10.1371/journal.pone.0220230.g002
The ZOOM Study
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overall the study is not representative of the UK eligible population for the shingles vaccine.
Also, practices were mostly located in the urban areas. People living in a care home or assisted
accommodation were overrepresented when compared with an estimate of only 3% in 2011
among 75–84 years old UK residents [40]. This may have led to recall bias, thus explaining the
high proportion for some items answered as “I don’t know/remember”; however, this bias
could not be quantified. Our study was not designed to assess the role of ethnicity as a determi-
nant of shingles vaccine uptake; yet a recent publication has suggested plays a role in shingles
vaccine uptake [41]. This aspect requires further detailed investigation. The proportion of
white participants in our sample was in line with census data for elderly patients (99.8% white
people in Northern Ireland, 95.1% in England and Wales and 99.2% in Scotland) [42–44]. Our
achieved response rate was approximately 20% which is low but is in line with what was
expected for such a study and consistent with earlier similar research [23]. A larger proportion
of responders were vaccinated (70.1%) compared to the initial target 50%±10% which may
indicate participation bias as individuals responding to the survey were more compliant with
vaccination. it should be noted that only the older catch-up cohort for shingles vaccination
campaign was assessed, to avoid a possible influence on the vaccination behaviour after the
study among the participants. Therefore, this limits the ability to generalise the results to a
younger population in a context of a different immunisation programme.
The study also has methodological strengths. The assessed variables were based on a well-
established conceptual model (HBM) and recent research on socio-psychological vaccination
determinants. GP practices were selected from CPRD, which is considered representative of
GP practices throughout the UK, and the number of individuals per practice was capped to
avoid cluster effects. The regression model generated in this study comprised a comprehensive
set of variables, which have been previously associated with preventive health-seeking behav-
iour. The objective assessment of vaccination status using an electronic database rather than
self-reported data addresses a key limitation of many similar studies in the field.
Policy and practice recommendations
To improve individuals’ knowledge about shingles, the messages conveyed to the public should
emphasise the cause of shingles, how it is triggered and the possible complications, such as
PHN. In addition, current results suggest that people who had shingles in the past may not
know the vaccine can protect them from future episodes. Whilst future research is required to
further explore this hypothesis, current campaigns should encourage the uptake of the vaccine
among those who experienced shingles in the past. The results of this study suggest that despite
both vaccinated and unvaccinated responders learned about the shingles vaccine at the GP
practice, being offered the vaccine directly by a HCP seems to be key in their decision-making
process. Therefore, vaccination campaigns should focus on the HCPs, given the importance of
the recommendations of these professionals on vaccination uptake.
We also found that less than half of the GPs surveyed were aware of local communication
campaigns regarding the shingles vaccine, but the majority considered their practices had
internal procedures/guidelines, materials and sufficient staff to provide vaccine information.
These results indicate that knowledge about the vaccine at GP practice level can be improved
notably on the economic burden of shingles to society, the duration of protection of the shin-
gles vaccine and vaccine effectiveness confirmed by recent findings conducted on the 3 first
years of the UK vaccination programme [3,45,46]. Communication campaigns should empha-
sise to HCPs the relevance of engaging with their patients to understand their motivation and
concerns regarding the shingles vaccine as an important lever to improve vaccination
coverage.
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Conclusion
The UK’s national immunisation program to prevent shingles has proved successful in pre-
venting this debilitating condition, but its benefits are dependent on the uptake of the shingles
vaccine. Our study suggests that policy amenable socio-psychological factors can explain the
likelihood of vaccination uptake for this condition better than socio-demographic factors
alone. Being proactively offered the shingles vaccine by a GP or a nurse, perceiving to be at
risk of developing shingles and perceived self-efficacy are associated with shingles vaccination
uptake. Our results further add to the existing evidence that HCPs have a pivotal role in pro-
moting herpes zoster vaccination. Future campaigns should focus on GPs and offer eligible
members of the public accessible information regarding shingles to further promote vaccina-
tion uptake.
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